Stifel Reiterates Buy Rating on Apellis Pharmaceuticals (APLS), 'we think the entire package presents a relatively convincing picture'
Tweet Send to a Friend
Stifel analyst Annabel Samimy reiterated a Buy rating and $60.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).The analyst comments "While ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
